FDA clears targeted cholangiocarcinoma therapy
-
By
-
Kathryn Wighton
-
September 24, 2026
-
2 min
By
Kathryn Wighton
September 24, 2026
Recurrent arterial embolization prompted surgery after imaging suggested thrombus, but definitive pathology revealed malignancy.
November 4, 2026
Traditional approval narrows eligibility for previously treated solid tumors after efficacy was not confirmed at lower biomarker levels.
by Mouj Hijazi
October 23, 2026
Phase 3 findings showed longer median progression-free survival with zanidatamab-containing regimens vs trastuzumab plus chemotherapy.
August 25, 2026